Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | LY2090314 + Simmiparib |
Synonyms | |
Therapy Description | |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
LY2090314 | LY-2090314|LY 2090314 | GSK3 Inhibitor (Pan) 3 | LY2090314 inhibits glycogen synthase kinase 3 (GSK3), therefore activates Wnt signaling pathway and leads to apoptosis in tumor cells (PMID: 25915038, PMID: 26735141, PMID: 32391602). | |
Simmiparib | SMOCL-9112 | PARP Inhibitor (Pan) 31 | Simmiparib is an inhibitor of PARP1/2, which may induce DNA double-strand breaks, G2/M phase arrest, and apoptotic activity, and may lead to inhibition of tumor growth (PMID: 27847302). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|